Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anamorelin crossover trial in malignant pleural mesothelioma cachexia
ACTRN12619001324101Phase 2Terminated
- Sponsor
- Institute for Respiratory Health
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of anamorelin in pleural mesothelioma and cancer anorexia-cachexia syndrome (CACS), sponsored by Institute for Respiratory Health. Primary endpoint: Change in appendicular skeletal muscle mass. Started Feb 2020; status: terminated.
02
Drugs
anamorelin
03
Conditions
pleural mesotheliomacancer anorexia-cachexia syndrome (CACS)
Beyond the preview
Go deeper on ACTRN12619001324101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619001324101.